Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers

NCT05672966 is registered in ClinicalTrials.gov with Wuhan BravoVax Co., Ltd. as lead sponsor.

NCT NCT05672966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05672966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers
Lead sponsor
Wuhan BravoVax Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 1, 2023
Completion date
October 31, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection